In the AXSANA/EUBREAST 3(R) study, researchers compared data about recurrence outcomes of more-invasive and less-invasive lymph node procedures.
AccuStem Sciences, Inc. (OTCQB: ACUT ), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, today announced the execution of a pilot study ...
Initial study will enable further collaboration on the predictive capabilities of StemPrintERPHOENIX, Jan. 08, 2026), a clinical stage diagnostics company dedicated to improving outcomes for patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback